180869-36-7

Basic information

• Product Name: 4-(Dimethoxymethyl)-2-(methylthio)-pyrimidine
• Synonyms: 4-(Dimethoxymethyl)-2-(methylthio)-pyrimidine;Pyrimidine,4-(dimethoxymethyl)-2-(methylthio)-;2-methylthiopyrimidine-4-carboxaldehyde dimethyl acetal
• CAS NO: 180869-36-7
• Molecular Formula: C₈H₁₂N₂O₂S
• Molecular Weight: 200.26
• Product Categories: pharmacetical
• Mol File: 180869-36-7.mol
• Article Data: 26

Chemical Properties

• Boiling Point: 273.033 °C at 760 mmHg
• Flash Point: 118.927 °C
• Appearance: /
• Density: 1.189 g/cm³
• Vapor Pressure: 0.01mmHg at 25°C
• Refractive Index: 1.534
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 0.37±0.31(Predicted)
• CAS DataBase Reference: 4-(Dimethoxymethyl)-2-(methylthio)-pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Dimethoxymethyl)-2-(methylthio)-pyrimidine(180869-36-7)
• EPA Substance Registry System: 4-(Dimethoxymethyl)-2-(methylthio)-pyrimidine(180869-36-7)

Safety Data

• Hazardous Substances Data: 180869-36-7(Hazardous Substances Data)

Usage

General Description

4-(Dimethoxymethyl)-2-(methylthio)-pyrimidine is a chemical compound with the molecular formula C8H12N2O2S. It is a pyrimidine derivative with two methoxy groups attached to the carbon atom and a methylthio group attached to the nitrogen atom. 4-(Dimethoxymethyl)-2-(methylthio)-pyrimidine has potential applications in the pharmaceutical and agricultural industries due to its ability to inhibit the growth of certain pathogens and parasites. Its unique molecular structure makes it a promising candidate for the development of new drugs and pesticides. Further research and development are needed to fully understand the potential uses and benefits of 4-(Dimethoxymethyl)-2-(methylthio)-pyrimidine.

InChI:InChI=1/C8H12N2O2S/c1-11-7(12-2)6-4-5-9-8(10-6)13-3/h4-5,7H,1-3H3

Upstream product

• 6342-56-9 Pyruvic aldehyde dimethyl acetal 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 74-88-4 methyl iodide 
• 7732-18-5 water 
• 17356-08-0 thiourea 
• 67751-23-9 4-(dimethylamino)-1,1-dimethoxy-but-3-en-2-one 
• 124-41-4 sodium methylate 
• 67751-23-9 (E)-4-(dimethylamino)-1,1-dimethoxybut-3-en-2-one 
• 2986-19-8 carbamimidothioic acid methyl ester 

Downstream Products

• 1074-68-6 4-formyl-2-(methylthio)pyrimidine 
• 219729-65-4 2-(propylthio)pyrimidine-4-carboxaldehyde 
• 1312662-00-2 (Z)-5-((2-(4-(p-tolyl)piperazin-1-yl)pyrimidin-4-yl)methylene)thiazolidine-2,4-dione 
• 1312663-13-0 (Z)-5-((2-(cyclohexyl(methyl)amino)pyrimidin-4-yl)methylene)thiazolidine-2,4-dione 

Relevant articles and documents

Discovery of S64315, a Potent and Selective Mcl-1 Inhibitor

Myeloid cell leukemia 1 (Mcl-1) has emerged as an attractive target for cancer therapy. It is an antiapoptotic member of the Bcl-2 family of proteins, whose upregulation in human cancers is associated with high tumor grade, poor survival, and resistance to chemotherapy. Here we report the discovery of our clinical candidate S64315, a selective small molecule inhibitor of Mcl-1. Starting from a fragment derived lead compound, we have conducted structure guided optimization that has led to a significant (3 log) improvement of target affinity as well as cellular potency. The presence of hindered rotation along a biaryl axis has conferred high selectivity to the compounds against other members of the Bcl-2 family. During optimization, we have also established predictive PD markers of Mcl-1 inhibition and achieved both efficient in vitro cell killing and tumor regression in Mcl-1 dependent cancer models. The preclinical candidate has drug-like properties that have enabled its development and entry into clinical trials.

Macrocyclic MCL-1 inhibitors and methods of use

The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES

The present invention relates to new compounds that are useful in the prevention or treatment of respiratory diseases, such as asthma, to the preparation of the compounds, and to compositions including the compounds. The present invention also relates to the use of the compounds, as well as compositions including the compounds, in treating or preventing respiratory diseases.